Sanofi will acquire Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders.
Sanofi hosted a conference call & webcast on the acquisition for the financial community
INVESTOR PRESENTATIONS • January 22, 2018
Sanofi will acquire Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders.
Sanofi hosted a conference call & webcast on the acquisition for the financial community
If you wish to continue to this external website, click Proceed.
It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.